MA52412A - Nouveaux composés sulfonimidoylpurinone substitués en position 7 et dérivés pour le traitement et la prophylaxie du cancer du foie - Google Patents
Nouveaux composés sulfonimidoylpurinone substitués en position 7 et dérivés pour le traitement et la prophylaxie du cancer du foieInfo
- Publication number
- MA52412A MA52412A MA052412A MA52412A MA52412A MA 52412 A MA52412 A MA 52412A MA 052412 A MA052412 A MA 052412A MA 52412 A MA52412 A MA 52412A MA 52412 A MA52412 A MA 52412A
- Authority
- MA
- Morocco
- Prior art keywords
- prophylaxis
- derivatives
- treatment
- new
- liver cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018077501 | 2018-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52412A true MA52412A (fr) | 2021-06-02 |
Family
ID=65685310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052412A MA52412A (fr) | 2018-02-28 | 2019-02-26 | Nouveaux composés sulfonimidoylpurinone substitués en position 7 et dérivés pour le traitement et la prophylaxie du cancer du foie |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3758707A1 (ja) |
| JP (1) | JP7089596B2 (ja) |
| KR (1) | KR20200128414A (ja) |
| CN (1) | CN111801100B (ja) |
| AR (1) | AR114419A1 (ja) |
| AU (1) | AU2019228654A1 (ja) |
| BR (1) | BR112020016509A2 (ja) |
| CA (1) | CA3091950A1 (ja) |
| CL (1) | CL2020002139A1 (ja) |
| CO (1) | CO2020010306A2 (ja) |
| IL (1) | IL276817A (ja) |
| MA (1) | MA52412A (ja) |
| MX (1) | MX2020008746A (ja) |
| PE (1) | PE20211456A1 (ja) |
| PH (1) | PH12020551343A1 (ja) |
| RU (1) | RU2020131012A (ja) |
| SG (1) | SG11202008291XA (ja) |
| TW (1) | TW202003518A (ja) |
| WO (1) | WO2019166432A1 (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20170169A1 (ar) | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| JP7065989B2 (ja) | 2018-02-28 | 2022-05-12 | ノバルティス アーゲー | インフルエンザを処置するためのオルソミクソウイルス複製の阻害剤としての１０－（ジ（フェニル）メチル）－４－ヒドロキシ－８，９，９ａ，１０－テトラヒドロ－７Ｈ－ピロロ［１’，２’：４，５］ピラジノ［１，２－ｂ］ピリダジン－３，５－ジオン誘導体および関連化合物 |
| KR102409595B1 (ko) | 2020-06-29 | 2022-06-17 | 한국과학기술연구원 | 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체 |
| CN112420196A (zh) * | 2020-11-20 | 2021-02-26 | 长沙市弘源心血管健康研究院 | 急性心肌梗死患者5年内生存率的预测方法和系统 |
| WO2024013205A1 (en) * | 2022-07-14 | 2024-01-18 | F. Hoffmann-La Roche Ag | Phosphorylpurinone compounds for the treatment of cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4189048B2 (ja) * | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | 複素環化合物 |
| TW201639852A (zh) | 2008-12-09 | 2016-11-16 | 吉李德科學股份有限公司 | 用於製備可用作類鐸受體調節劑之化合物的中間體化合物 |
| CA2760766A1 (en) * | 2009-05-21 | 2010-11-25 | Nicholas James Bennett | Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases |
| US8962652B2 (en) * | 2009-10-22 | 2015-02-24 | Gilead Sciences, Inc. | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
| US20110150836A1 (en) * | 2009-12-22 | 2011-06-23 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
| ES2691671T3 (es) | 2010-06-24 | 2018-11-28 | Alkermes Pharma Ireland Limited | Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato |
| US20120039916A1 (en) * | 2010-08-13 | 2012-02-16 | Baylor Research Institute | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
| SI3294740T1 (sl) * | 2015-05-08 | 2019-12-31 | F. Hoffmann-La Roche Ag | Nove sulfonimidoilpurinonske spojine in derivati za zdravljenje virusne okužbe in zaščito pred njo |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| WO2018041763A1 (en) | 2016-08-29 | 2018-03-08 | F. Hoffmann-La Roche Ag | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
| JP7101663B2 (ja) * | 2016-09-13 | 2022-07-15 | エフ．ホフマン－ラ ロシュ アーゲー | Ｔｌｒ７アゴニストとｈｂｖキャプシドアセンブリ阻害剤の併用療法 |
-
2019
- 2019-02-26 EP EP19708981.6A patent/EP3758707A1/en active Pending
- 2019-02-26 CA CA3091950A patent/CA3091950A1/en active Pending
- 2019-02-26 WO PCT/EP2019/054729 patent/WO2019166432A1/en active Application Filing
- 2019-02-26 MX MX2020008746A patent/MX2020008746A/es unknown
- 2019-02-26 MA MA052412A patent/MA52412A/fr unknown
- 2019-02-26 BR BR112020016509-3A patent/BR112020016509A2/pt not_active Application Discontinuation
- 2019-02-26 SG SG11202008291XA patent/SG11202008291XA/en unknown
- 2019-02-26 RU RU2020131012A patent/RU2020131012A/ru unknown
- 2019-02-26 CN CN201980015912.7A patent/CN111801100B/zh active Active
- 2019-02-26 PE PE2020001228A patent/PE20211456A1/es unknown
- 2019-02-26 JP JP2020544794A patent/JP7089596B2/ja active Active
- 2019-02-26 KR KR1020207027935A patent/KR20200128414A/ko unknown
- 2019-02-26 AU AU2019228654A patent/AU2019228654A1/en not_active Abandoned
- 2019-02-27 TW TW108106752A patent/TW202003518A/zh unknown
- 2019-02-28 AR ARP190100505A patent/AR114419A1/es unknown
-
2020
- 2020-08-19 CL CL2020002139A patent/CL2020002139A1/es unknown
- 2020-08-19 IL IL276817A patent/IL276817A/en unknown
- 2020-08-21 CO CONC2020/0010306A patent/CO2020010306A2/es unknown
- 2020-08-27 PH PH12020551343A patent/PH12020551343A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL276817A (en) | 2020-10-29 |
| AR114419A1 (es) | 2020-09-02 |
| BR112020016509A2 (pt) | 2020-12-15 |
| CO2020010306A2 (es) | 2020-08-31 |
| PH12020551343A1 (en) | 2021-06-21 |
| PE20211456A1 (es) | 2021-08-05 |
| EP3758707A1 (en) | 2021-01-06 |
| KR20200128414A (ko) | 2020-11-12 |
| WO2019166432A1 (en) | 2019-09-06 |
| CN111801100A (zh) | 2020-10-20 |
| JP7089596B2 (ja) | 2022-06-22 |
| AU2019228654A1 (en) | 2020-09-03 |
| MX2020008746A (es) | 2020-09-28 |
| RU2020131012A (ru) | 2022-03-28 |
| SG11202008291XA (en) | 2020-09-29 |
| CN111801100B (zh) | 2023-10-24 |
| CA3091950A1 (en) | 2019-09-06 |
| TW202003518A (zh) | 2020-01-16 |
| JP2021514972A (ja) | 2021-06-17 |
| CL2020002139A1 (es) | 2021-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52412A (fr) | Nouveaux composés sulfonimidoylpurinone substitués en position 7 et dérivés pour le traitement et la prophylaxie du cancer du foie | |
| MA51200A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
| MA55959A (fr) | Dosage d'inhibiteur de kras pour le traitement de cancers | |
| MA52780A (fr) | Inhibiteurs de kras g12c pour le traitement du cancer | |
| MA45146A (fr) | Dérivés de pyrazolopyridine pour le traitement du cancer | |
| MA51796A (fr) | Procédés et compositions pour l'administration de protéines thérapeutiques | |
| MA52232A (fr) | Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer | |
| MA51139A (fr) | Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer | |
| MX2018005694A (es) | 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas. | |
| MA42136A (fr) | Anticorps anti-cd38 pour le traitement de l'amyloïdose à chaînes légères et d'autres tumeurs malignes hématologiques positives à cd38 | |
| MA44737A (fr) | Compositions pour le traitement de troubles liés à l'hyperkératose | |
| MA56019A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA55560A (fr) | Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer | |
| MA50391A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires | |
| MA52873A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA54515A (fr) | Dérivés de quinoléine destinés à être utilisés dans le traitement de maladies inflammatoires | |
| MA52861A (fr) | Méthodes et compositions pour le traitement de l'apnée du sommeil | |
| MA49576A (fr) | Compositions et méthodes pour le traitement d'infections fongiques | |
| MA55148A (fr) | Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance | |
| MA51056A (fr) | Compositions et méthodes pour le traitement d'affections métaboliques | |
| MA44864A (fr) | Trithérapie pour le traitement d'une maladie intestinale inflammatoire | |
| MA52971A (fr) | Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle | |
| MA53873A (fr) | Compositions et procédés pour le traitement de la presbytie | |
| MA56508A (fr) | Inhibiteur d'egfr pour le traitement du cancer |